Quantitative urinary KRAS for treatment decisions in patients with metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Melnikova, Vladislava
Vibat, Cecile Rose T.
Ning, Van
Agafitei, Raluca Dana
Hanna, Diana L.
Hancock, Saege
Erlander, Mark G.
Lenz, Heinz-Josef
Barzi, Afsaneh
机构：
[1] Trovagene Inc, San Diego, CA USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Univ Southern Calif, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15011
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Metastatic colorectal cancer (mCRC) treatment patterns in the Medicare population
    Snider, Jeremy
    Wang, Ed
    Anderson, Sibyl
    Steelquist, Jordan
    Warnick, Greg S.
    Fedorenko, Catherine R.
    Shankaran, Veena
    Ramsey, Scott David
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [22] Impact of RAS testing on treatment duration among patients with metastatic colorectal cancer (mCRC).
    Bach, Bruce A.
    Christodoulopoulou, Alexandra
    Klink, Andrew
    Hechmati, Guy
    Mujumdar, Urvi
    Feinberg, Bruce A.
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [23] AWARENESS AND PENETRATION OF KRAS MUTATION TESTING IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ciardiello, F.
    Wohlschlegel, B.
    Teague, T.
    Mercadante, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 20 - 20
  • [24] Characteristics and treatment effect of senior patients with metastatic colorectal cancer (mCRC): A retrospective analysis
    Boudreault, J.
    Aubin, F.
    Ayoub, J. M.
    Sylvestre, M.
    Richard, C. S.
    Tehfe, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [25] Awareness and penetration of KRAS mutation testing in the treatment of patients with metastatic colorectal cancer
    Ciardiello, F.
    Wohlschlegel, B.
    Teague, T.
    Mercadante, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Capecitabine and oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (MCRC)
    Karacetin, D.
    Maral, O.
    Yalcyn, B.
    Okten, B.
    Incekara, O.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [27] Kras in metastatic colorectal cancer
    Wicki, Andreas
    Herrmann, Richard
    Christofori, Gerhard
    SWISS MEDICAL WEEKLY, 2010, 140 : 14 - 19
  • [28] Survival outcomes in US patients with metastatic colorectal cancer (mCRC)
    Knopf, Kevin
    Iqbal, Sheikh Usman
    Thompson, Stephen F.
    Malangone, Elisabetta
    Gorritz-Kindu, Magdaliz
    Stern, Lee
    Sherman, Steven A.
    Naoshy, Sarah
    Wooten, Michael
    Andria, Michael L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [29] KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
    Van Cutsem, E.
    Lang, I.
    D'haens, G.
    Moiseyenko, V.
    Zaluski, J.
    Folprecht, G.
    Tejpar, S.
    Kisker, O.
    Stroh, C.
    Rougier, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Survival for patients with resectable lung metastatic colorectal cancer (mCRC).
    Price, Timothy Jay
    Tomita, Yoko
    Beeke, Carol
    Padbury, Robert
    Townsend, Amanda Rose
    Maddern, Guy
    Roy, Amitesh
    Roder, David
    Karapetis, Christos Stelios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345